Transcatheter occlusion promising for uterine leiomyomata

Article

-->

Results of a small study presented at the recent ACOG meeting adds to the growing body of evidence suggesting that transcatheter uterine artery occlusion (UAO) with coils is a promising alternative to standard uterine artery embolization (UAE) in women with heavy uterine bleeding associated with uterine leiomyomata. Women undergoing UAO (n=6) had less postprocedural pain than UAE patients; six of eight UAE patients but none of the UAO patients required parenteral narcotics in the recovery room. In addition, women undergoing UAO had significantly shorter hospital stays (1 vs. 6 nights, respectively) than UAE patients. Pain scores at 1 week and Ruta bleeding scores at 3 months were similar. The study authors, from Kaiser Los Angeles Medical Center (Los Angeles, Calif.) point out that larger-scale studies with longer follow-up are required to confirm these results and further elucidate the efficacy of transcatheter UAO.

Cunningham ES, Terasaki K, Ngo M, et al. Uterine artery embolization compared with occlusion for uterine leiomyomata. Obstet Gynecol. 2007;109(suppl):8S.

Related Videos
Understanding combined oral contraceptives and breast cancer risk | Image Credit: health.ucdavis.edu
Why doxycycline PEP lacks clinical data for STI prevention in women
The importance of nipocalimab’s FTD against FNAIT | Image Credit:  linkedin.com
Enhancing cervical cancer management with dual stain | Image Credit: linkedin.com
Fertility treatment challenges for Muslim women during fasting holidays | Image Credit: rmanetwork.com
Understanding the impact of STIs on young adults | Image Credit: providers.ucsd.edu.
CDC estimates of maternal mortality found overestimated | Image Credit: rwjms.rutgers.edu.
Study unveils maternal mortality tracking trends | Image Credit: obhg.com
How Harmonia Healthcare is revolutionizing hyperemesis gravidarum care | Image Credit: hyperemesis.org
Unveiling gender disparities in medicine | Image Credit:  findcare.ahn.org.
Related Content
© 2024 MJH Life Sciences

All rights reserved.